US EditionFDA moves to exclude weight loss drugs from compounding chemicals list
The agency said there is no shortage and no clinical need for outsourcing facilities to compound semaglutide, tirzepatide and liraglutide.
6 Articles
6 Articles
What did FDA propose about compounding weight-loss drugs?
FDA proposal targets compounding using obesity and diabetes drug ingredients The U.S. Food and Drug Administration has proposed excluding the active ingredients in certain widely used weight loss and diabetes medicines from a list of substances that can be used in compounding. The move is aimed at…
OECD: 54% of adults in member countries suffer from obesity or overweightThe U.S. Drug Regulatory Agency announced on Thursday its intention to tighten the control of copies of certain treatments against diabetes and obesity, such as Ozempic.The Food and Drug Administration (FDA) seeks to further restrict the possibility of legally manufacturing alternative versions of these drugs. “When FDA-approved drugs exist, FDA-supervised drug production p…
The U.S. drug regulatory agency announced Thursday its intention to tighten controls on counterfeit versions of certain diabetes and obesity treatments, such as Ozempic. The Food and Drug Administration (FDA) seeks to further restrict the possibility of legally manufacturing alternative versions of these drugs. "When FDA-approved drugs exist, FDA-supervised drug manufacturing facilities cannot legally produce compounds from bulk active ingredien…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
